Business Wire

Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and ...
FierceBiotech

Tris builds clinical case for opioid alternative by showing its pain drug is less likely to be abused

Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of clinical data to show that the drug is less likely to be abused. The phase 1 ...
FiercePharma

Tris Pharma, a CMO for Pfizer, hit with FDA warning letter for ADHD drug, morphine solution

Tris Pharma, a New Jersey-based CMO that manufactures the ADHD drug Quillivant for Pfizer, was hit with a warning letter by the FDA that cited significant violations. In the letter dated March 26, the ...
Business Wire

Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of ...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ALLEVIATE-2 Phase 3 pivotal clinical ...